Monica Goldberg is a prominent inventor based in Spring House, Pennsylvania. She has made significant contributions to the field of cancer treatment through her innovative work in antibody development. With a total of two patents to her name, her research focuses on enhancing the efficacy of immune responses against cancer.

Latest Patents

Monica's latest patents include the invention of humanized anti-CD134 (OX40) antibodies and their uses. This invention provides antibodies that specifically bind to human CD134, which is expressed on activated human conventional effector CD4 and/or CD8 T lymphocytes (Teffs) and on activated human suppressive regulatory CD4 T lymphocytes (Tregs). These humanized anti-human CD134 antibodies are designed to empower Teffs' anti-cancer effector function and inhibit Tregs' suppressive function, making them valuable for cancer treatment.

Career Highlights

Throughout her career, Monica has worked with notable companies such as Biocerox Products B.V. and Janssen Pharmaceuticals, Inc. Her experience in these organizations has allowed her to develop her expertise in the field of immunology and cancer therapeutics.

Collaborations

Monica has collaborated with esteemed colleagues, including Petrus Johannes Simons and Louis Boon. These partnerships have contributed to her innovative research and the advancement of her patented technologies.

Conclusion

Monica Goldberg is a trailblazer in the development of cancer treatment solutions through her innovative antibody research. Her contributions to the field are paving the way for new therapeutic approaches in oncology.

This text is generated by artificial intelligence and may not be accurate.